A Case Report of a Patient with HER2-Positive Metastatic Breast Cancer on Dialysis, Who Responded to Ado- Trastuzumab Emtansine

Elia Sais and Sonia Del Barco

University Hospital Doctor Josep Trueta, The Catalan Institute of Oncology (ICO), Medical Oncology Service, Girona, Spain

^*Correspondance to: Sonia Del Barco 

 PDF  Full Text Case Report | Open Access

Abstract:

Introduction: Ado-trastuzumab emtansine (T-DM1) is a human epidermal growth factor receptor 2 (HER2)-targeted drug that comprises trastuzumab, a stable linker, and the potent cytotoxic agent derivative of maytansine (DM1). Once T DM1 binds to the HER2 receptor, it allows intracellular drug delivery specifically to HER2-overexpressing cells, minimizing the exposure of the drug to normal tissue.Case: We report the case report of a 47-year old woman with HER2-positive metastatic breast cancer (MBC) on dialysis, which was treated with T-DM1. The tolerance of T-DM1 in this patient was predictable and good and the patient achieved a durable response.Discussion and Conclusions: A previous exploratory analysis has shown that the pharmacokinetic properties of T-DM1 are unaffected by age, race or renal function. However, there are no specific trials for patients with severe renal impairment treated with T-DM1. Only one patient with these characteristics has been treated before with T-DM1, although no dosage recommendation was given.

Keywords:

Antibodies; Antineoplastic agents; Breast neoplasms; Monoclonal; Renal dysfunction

Cite the Article:

Sais E, Del Barco S. A Case Report of a Patient with HER2-Positive Metastatic Breast Cancer on Dialysis, Who Responded to Ado-Trastuzumab Emtansine. Ann Clin Case Rep. 2017; 2: 1471.